MRNA Jan 2023 310.000 call
| Previous close | 1.9600 |
| Open | 1.5100 |
| Bid | 1.4600 |
| Ask | 2.2000 |
| Strike | 310.00 |
| Expiry date | 2023-01-20 |
| Day's range | 1.5100 - 1.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | 524 |
- Motley Fool
Why Sanofi May Be a Frontrunner in Endemic COVID-19
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
- Motley Fool
If You Invested $10,000 in Moderna 2 Years Ago, This Is How Much You Would Have Today
Moderna (NASDAQ: MRNA) was one of the best stocks to own last year as it brought its COVID-19 vaccine to market and generated billions in revenue. The company, which was a bit of an unknown before the pandemic began, has quickly risen in popularity.
- Motley Fool
1 Green Flag for Moderna's Fall Vaccine Plan, and 1 Red Flag
Moderna (NASDAQ: MRNA) took center stage when it launched its coronavirus vaccine about a year and a half ago. Moderna recently reported that its booster candidate offers "superior" performance against the omicron variant.
